Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Daniel Klee

Interventional Cardiology Chandler, AZ Medical Doctor

NPI 1225013824 CMS profile 10473

2075 W Pecos Rd, Ste 1, Chandler, AZ 85224

Open in the dashboard

General payments

$9,155

485 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Daniel Klee of Chandler, AZ is reported in the CMS Open Payments database as having received $9,155 across 485 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $585 26
2022 General $2,537 129
2021 General $2,056 105
2020 General $1,868 103
2019 General $2,109 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Klee
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Daniel Klee were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Daniel Klee Interventional Cardiology median Middle half National median
2019 $2,109 $1,097 $329–$3,048 $163
2020 $1,868 $473 $161–$1,480 $114
2021 $2,056 $677 $233–$1,827 $132
2022 $2,537 $978 $333–$2,724 $149
2023 $585 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $776 60 payments
  2. Novartis Pharmaceuticals Corporation $757 44 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $688 38 payments
  4. Abbott Laboratories $597 23 payments
  5. AstraZeneca Pharmaceuticals LP $518 28 payments
  6. Edwards Lifesciences Corporation $468 17 payments
  7. Pfizer Inc. $457 34 payments
  8. Actelion Pharmaceuticals US, Inc. $413 15 payments
  9. Amgen Inc. $402 29 payments
  10. Sanofi-Aventis U.S. LLC $337 22 payments
  11. Other $3,742 175 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,764 474 payments
  2. Education $378 10 payments
  3. Consulting Fee $13 1 payment
Products named General payments · program years 2019–2023
  1. XARELTO $776 60 payments
  2. ENTRESTO $700 41 payments
  3. LifeVest $688 38 payments
  4. BRILINTA $442 23 payments
  5. OPSUMIT $413 15 payments
  6. Repatha $402 29 payments
  7. ELIQUIS $375 27 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $274 8 payments
  9. JARDIANCE $268 15 payments
  10. (5044) MCOT $257 12 payments
  11. Other $5,339 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

485 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record